Register a trial

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03784625




Registration number
NCT03784625
Ethics application status
Date submitted
18/12/2018
Date registered
24/12/2018

Titles & IDs
Public title
Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012
Scientific title
Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012: Phase I Study
Secondary ID [1] 0 0
TRANSLA12-143
Secondary ID [2] 0 0
2016-002444-17
Universal Trial Number (UTN)
Trial acronym
MELRIV-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Melanoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Malignant melanoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - [131I]ICF01012 (therapeutic dose level 1)
Treatment: Drugs - [131I]ICF01012 (therapeutic dose level 2)
Treatment: Drugs - [131I]ICF01012 (therapeutic dose level 3)
Treatment: Drugs - [131I]ICF01012 (therapeutic dose level 4)

Experimental: therapeutic dose activity (level 1) - \[131\]ICF01012 at a therapeutic dose of 800 MBq/m² , single dose at D11 (intravenous administration)

Experimental: therapeutic dose activity (level 2) - \[131\]ICF01012 at a therapeutic dose of 1600 MBq/m² , single dose at D11 (intravenous administration)

Experimental: therapeutic dose activity (level 3) - \[131\]ICF01012 at a therapeutic dose of 2700 MBq/m² , single dose at D11 (intravenous administration)

Experimental: therapeutic dose activity (level 4) - \[131\]ICF01012 at a therapeutic dose of 4000 MBq/m² , single dose at D11 (intravenous administration)


Treatment: Drugs: [131I]ICF01012 (therapeutic dose level 1)
* 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)
* 1 therapeutic injection (D11) at a dose of 800 MBq/m²

Treatment: Drugs: [131I]ICF01012 (therapeutic dose level 2)
* 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)
* 1 therapeutic injection (D11) at a dose of 1600 MBq/m²

Treatment: Drugs: [131I]ICF01012 (therapeutic dose level 3)
* 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)
* 1 therapeutic injection (D11) at a dose of 2700 MBq/m²

Treatment: Drugs: [131I]ICF01012 (therapeutic dose level 4)
* 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)
* 1 therapeutic injection (D11) at a dose of 4000 MBq/m²
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Evaluation of the recommended therapeutic dose of [131I] ICF01012
Timepoint [1] 0 0
Only toxicities observed during the 6 weeks following administration of the therapeutic dose will be considered for the evaluation of DLT
Secondary outcome [1] 0 0
Evaluation of the sensitivity and specificity by patients and by lesions of [131I]ICF01012 ICF01012 for the visualization of metastatic melanoma lesions from the examinations made during the selection phase
Timepoint [1] 0 0
selection phase Day 0 - Day 7
Secondary outcome [2] 0 0
Evaluation of the tolerance of [131I] ICF01012 (adverse events assessed by NCI-CTC Version 4.03)
Timepoint [2] 0 0
from the the first dose to the end of study (3 months after diagnostic dose)
Secondary outcome [3] 0 0
Pharmacokinetics of [131I] ICF01012 including the study of biodistribution and excretion (radiation counting of serum, whole blood and urinary samples)
Timepoint [3] 0 0
selection phase Day 0 (diagnostic dose), Day 1, and Day 4, Day 7
Secondary outcome [4] 0 0
Evaluation of the therapeutic response of [131I] ICF01012.
Timepoint [4] 0 0
at 3 months
Secondary outcome [5] 0 0
Evaluation of personal dosimetry for the administration of [131I]ICF01012.
Timepoint [5] 0 0
Selection phase : Day 0, Day 1, Day 4, and Day 7; therapeutic phase : Day 15, Day 18 and Day 25, Day 74

Eligibility
Key inclusion criteria
* Patient with metastatic melanoma failure to recommended treatments by HAS.
* Initial histological diagnosis of cutaneous melanoma pigmented or unknown status or choroidal melanoma.
* Presence of at least one measurable lesion and / or evaluable in 18FDG-PET as PERCIST criteria.
* Presence of at least one measurable lesion and / or evaluable as CT RECIST 1.1 criteria.
* WHO performance index = 2 .
* Age> 18 years
* Life expectancy> 3 months.
* Creatinine = 1,5 x ULN or creatinine clearance = 60ml/min if creatinine > 1,5 x ULN , Neutrophil > 1,5.109L-1, Platellets > 100 x 109L-1, prothrombine time < 1,3 x control, Hemoglobin > 9 g/dL, facteur V > 80% (or AST, ALT = 3 x LNS (= 5 x ULN if liver metastasis)).
* Normal cardiac fonction (LVEF> 40%).
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Brain metastases symptomatic
* Patient with a VI skin phototype
* Previous treatment with chemotherapy, radiotherapy, immunotherapy and targeted therapy in the previous 4 weeks, the first injection of [131I] ICF01012
* Pregnant woman, nursing or woman of childbearing age refusing to follow effective contraception during treatment and 12 months after the administration of therapeutic dose.
* Men refusing to follow effective contraception during treatment and 12 months after the administration of therapeutic dose
* Other evolutionary known cancer in the past five years
* Earlier irradiation of more than 25% of the bone marrow
* Suspicion of invasion of more than 25% of the bone marrow on imaging 18F-FDG PET-CT
* External Radiotherapy on target organs or the maximum dose as recommended in force
* Uncontrolled diabetes
* Known history of allergy to the excipients of the solution of [131I]ICF01012
* Any comorbidity or severe disease at the discretion of the investigator

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 0
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
18/10/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/01/2025
Actual
Sample size
Target
36
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
France
State/province [1] 0 0
Clermont-Ferrand

Funding & Sponsors
Primary sponsor type
Other
Name
Centre Jean Perrin
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Florent CACHIN, Pr
Address 0 0
Centre Jean Perrin
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Florent CACHIN, Pr
Address 0 0
Country 0 0
Phone 0 0
0473278089
Fax 0 0
Email 0 0
florent.CACHIN@clermont.unicancer.fr
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT03784625